Clinical Evidence For Both Weight Management Options
Switching From Wegovy To Mounjaro: Understanding The Clinical Difference
When switching from Wegovy to Mounjaro, it's essential to understand the fundamental mechanism differences between these prescription-only medicines. Wegovy contains semaglutide, which specifically targets GLP-1 receptors to reduce appetite and promote satiety after meals. Mounjaro, containing tirzepatide, acts as a dual agonist targeting both GIP and GLP-1 receptors, potentially offering a different therapeutic approach to weight management.
Patients considering switching from Wegovy to Mounjaro should discuss this transition with their prescriber, as both medications require careful dose escalation and ongoing monitoring. The decision to switch from Wegovy to Mounjaro isn't about one being superior to the other - rather, it's about finding the most appropriate treatment for individual patient circumstances. Both medications must be used alongside a reduced-calorie diet and increased physical activity, and both are available through EverydayMeds' comprehensive clinical assessment process.
UK Pricing For Switching From Wegovy To Mounjaro Options
Understanding the financial commitment when switching from Wegovy to Mounjaro is crucial for UK patients. Wegovy single pens start from £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. New customers benefit from discount code FIRST40, whilst returning customers use code DOSE25, both applied at checkout to reach these final prices.
For patients requiring consistent supply when switching from Wegovy to Mounjaro or maintaining their current treatment, our bundle options provide convenience without multiple orders. The Intro Trio (0.25mg, 0.5mg, 1mg) costs £299.99, whilst our Ultimate Stability Trio offers three months of 2.4mg maintenance supply for £649.99. These bundles ensure treatment continuity and reduce the administrative burden of frequent ordering, particularly important during any medication transition period.
Clinical Evidence From STEP Trials For Switching From Wegovy To Mounjaro Decisions
The decision process for switching from Wegovy to Mounjaro should consider the robust clinical evidence available for semaglutide. In the landmark STEP 1 trial, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo, as reported by Wilding et al. in the New England Journal of Medicine, 2021.
Additional STEP trial data shows sustained efficacy, with STEP 5 demonstrating clinically studied weight loss maintained at two years, whilst STEP 3 showed clinically studied weight loss when combined with intensive behavioural therapy. The SELECT cardiovascular outcomes trial further demonstrated a 20% reduction in major cardiovascular events. These evidence-based results provide valuable context when discussing switching from Wegovy to Mounjaro with healthcare providers.
How Wegovy Works For Patients Switching From Wegovy To Mounjaro
Wegovy functions as a GLP-1 receptor agonist, mimicking the action of a natural hormone that regulates appetite and blood sugar levels. The medication works primarily by slowing gastric emptying, which helps patients feel fuller for longer periods after eating smaller portions. It also acts on appetite centres in the brain, potentially reducing food cravings and the desire to overeat. The once-weekly injection using the FlexTouch pen system provides consistent medication levels throughout the week. Patients must follow a mandatory dose escalation schedule, starting at 0.25mg and gradually increasing to the maintenance dose of 2.4mg over 16 weeks. This gradual increase helps minimise potential gastrointestinal side effects whilst allowing the body to adapt to the medication's appetite-suppressing effects.
Ordering Process For Switching From Wegovy To Mounjaro Assessment
EverydayMeds streamlines the clinical assessment process whether you're continuing with Wegovy or switching from Wegovy to Mounjaro. Our 3-minute online clinical questionnaire captures essential medical history, current medications, and weight management goals to support prescriber decision-making. Qualified prescribers review each application within three working days (or 24 hours with express service), ensuring appropriate clinical oversight for these prescription-only medicines. Once approved, medications are dispatched via next-day delivery using cold-chain temperature-controlled packaging to maintain product integrity. Our GPhC-registered pharmacy (#9012878) ensures all medications meet strict pharmaceutical standards from storage through to delivery. The entire process maintains clinical governance whilst providing convenient access to these important weight management treatments.
Storage Advantages When Switching From Wegovy To Mounjaro
Storage considerations present a practical advantage for patients switching from Wegovy to Mounjaro or those comparing options. Wegovy pens require refrigeration at 2-8°C before first use but can be stored at room temperature below 30°C for up to 6 weeks once removed from the fridge. This compares favourably to Mounjaro's 21-day room temperature limit, providing greater flexibility for travel or temporary storage situations. The FlexTouch pen system used with Wegovy offers reliable dose delivery with clear dosing windows and simple operation. Patients must complete their dose escalation schedule as prescribed, with each pen providing four doses at the appropriate strength. Proper storage ensures medication efficacy throughout the treatment period, whether patients are maintaining their current Wegovy regimen or transitioning to alternative treatments.
UK Patient Outcomes When Switching From Wegovy To Mounjaro
Real-world outcomes for UK patients provide valuable insights beyond clinical trial data when considering switching from Wegovy to Mounjaro. NICE guidance TA875 recommends Wegovy for eligible patients within specialist weight management programmes, recognising its place in comprehensive obesity treatment. Patient adherence studies suggest that the once-weekly dosing schedule improves compliance compared to daily medications, though individual responses vary significantly.
Long-term sustainability remains a key consideration when switching from Wegovy to Mounjaro or continuing current treatment. STEP trial extension data indicates that patients regained approximately two-thirds of lost weight within one year of stopping treatment, emphasising that weight management requires ongoing commitment rather than short-term intervention. This context helps inform realistic expectations and treatment planning discussions.
Making The Decision: Switching From Wegovy To Mounjaro Support
The choice between continuing Wegovy or switching from Wegovy to Mounjaro ultimately depends on individual patient factors, treatment response, and clinical circumstances. Both medications require prescription from qualified healthcare providers following thorough clinical assessment. EverydayMeds provides access to both treatments through our comprehensive online clinical service, ensuring patients receive appropriate medical oversight regardless of their chosen therapy. Our clinical team reviews each application against current prescribing guidelines, considering patient medical history, contraindications, and treatment goals. Remember that both Wegovy and Mounjaro are available from EverydayMeds - your prescriber can help determine which treatment approach is most appropriate for your individual circumstances and weight management journey.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
